MARKET

DRNA

DRNA

Dicerna
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.06
-0.16
-0.61%
After Hours: 26.26 +0.2 +0.77% 17:37 05/17 EDT
OPEN
26.33
PREV CLOSE
26.22
HIGH
26.66
LOW
25.68
VOLUME
335.76K
TURNOVER
--
52 WEEK HIGH
32.67
52 WEEK LOW
16.50
MARKET CAP
2.00B
P/E (TTM)
-16.2672
1D
5D
1M
3M
1Y
5Y
Bridger Management, Llc Buys Sotera Health Co, Microsoft Corp, Insulet Corp, Sells American ...
GuruFocus News · 3d ago
Dicerna to Participate in Upcoming Investor Conferences
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, wi...
BusinessWire · 5d ago
Goldman Sachs Says These 3 Stocks Could Surge Over 70% From Current Levels
Are we at the start of a boom or a bust? That’s the question on investors’ minds these days, as the world gets back on its feet following the COVID
TipRanks.com · 6d ago
Lilly, MiNA Ink Broad RNA Deal Worth $1.25B
Benzinga · 6d ago
Royalty Pharma Reports First Quarter 2021 Results
Double-digit growth in Net cash provided by operating activities (GAAP) and Adjusted Cash Flow(2) Announced transactions of up to $787 million in 2021,...
GlobeNewswire · 6d ago
Analysts Are Bullish on Top Healthcare Stocks: Dicerna Pharma (DRNA), ConforMIS (CFMS)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dicerna Pharma (DRNA) and ConforMIS (CFMS) with bullish
SmarterAnalyst · 05/10 13:45
Dicerna Pharmaceuticals (NASDAQ:DRNA) Is In A Strong Position To Grow Its Business
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St. · 05/10 08:28
Dicerna Pharma (DRNA) Received its Third Buy in a Row
After Goldman Sachs and Truist Financial gave Dicerna Pharma (NASDAQ: DRNA) a Buy rating last month, the company received another Buy, this time from H.C.
SmarterAnalyst · 05/07 10:47
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DRNA. Analyze the recent business situations of Dicerna through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DRNA stock price target is 39.67 with a high estimate of 48.00 and a low estimate of 34.00.
EPS
Institutional Holdings
Institutions: 262
Institutional Holdings: 74.26M
% Owned: 96.56%
Shares Outstanding: 76.90M
TypeInstitutionsShares
Increased
36
1.84M
New
23
2.59M
Decreased
44
2.87M
Sold Out
11
266.32K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Independent Director
J. Kevin Buchi
President/Chief Executive Officer/Director
Douglas Fambrough
Chief Financial Officer
Douglas Pagan
Chief Operating Officer/Executive Vice President
James Weissman
Executive Vice President/Chief Scientific Officer
Bob Brown
Senior Vice President/Director of Human Resources
Regina Paglia
Vice President
Hardean Achneck
Executive Vice President
Shreeram Aradhye
Vice President
Steven Kates
Other
Robert Ciappenelli
Other
David Caponera
Secretary
Ling Zeng
Other
Rob Ciappenelli
Independent Director
Stephen Doberstein
Independent Director
Martin Freed
Other
Rebecca Peterson
Independent Director
Patrick Gray
Independent Director
Stephen Hoffman
Independent Director
.. ..
Independent Director
Adam Koppel
Independent Director
Marc Kozin
Independent Director
Anna Protopapas
Independent Director
Cynthia Smith
No Data
About DRNA
Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. It is focused on development of RNAi-based therapeutics using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases and cardiovascular diseases. Its development programs include dacryocystorhinostomy (DCR)-PHXC for the treatment of primary hyperoxaluria (PH), which is in a Phase I clinical trial; DCR-HBVS for the treatment of chronic hepatitis B virus (HBV), which is in a Phase I clinical trial, and a product candidate against a rare liver disease. It also developed a wholly owned clinical candidate, DCR-BCAT, targeting the β-catenin oncogene. DCR-BCAT is delivered by its lipid nanoparticle (LNP) tumor delivery system, EnCore.

Webull offers kinds of Dicerna Pharmaceuticals Inc stock information, including NASDAQ:DRNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DRNA stock methods without spending real money on the virtual paper trading platform.